Abstract
The notion that fibrinogen is strongly, consistently, and independently related to coronary risk has been widely accepted. The evidence is based on numerous prospective epidemiological studies and clinical observations. However, the reasons why fibrinogen is elevated in coronary disease and in atherosclerosis are only incompletely understood. All cells involved in the atherogenetic process are able to produce cytokines which induce an acute phase reaction. The potential pathophysiologic mechanisms by which elevated fibrinogen levels mediate coronary risk are manifold: It forms the substrate for thrombin and represents the final step in the coagulation cascade; it is essential for platelet aggregation; it modulates endothelial function; it promotes smooth muscle cell proliferation and migration; it interacts with the binding of plasminogen with its receptor; and finally it represents a major acute phase protein. Whether or not fibrinogen is causally involved in atherothrombogenesis still remains to be determined, and even though other unsolved issues await conclusive answers, fibrinogen has emerged as an important additional marker of coronary risk.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Braunwald E: Shattuck Lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997, 337:1360–1369.
Ross R: Arteriosclerosis — an inflammatory disease. N Engl J Med 1999, 340:115–126.
•• Danesh J, Collins R, Appleby P, et al.: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. J Am Med Assoc 1998, 279:1477–1482.
Most recent meta-analysis of epidemiologic studies on fibrinogen and other markers of the acute phase response
•• Ernst E, Koenig W: Fibrinogen and cardiovascular risk. Vascular Medicine 1997, 2:115–125.
Most extensive review on the role of fibrinogen as a cardiovascular risk factor, its determinants, and its clinical implications
Caen JP, Dravet L, Montalescot, G: Abstracts Presented to the Fourth International Fibrinogen Symposium. Fibrinogen & Cardiovascular Disease. Blood Coagul Fibrinolysis 1999, (suppl 1):S91–S121.
Woodward M, Lowe GDO, Rumley A, et al.: Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study. Eur Heart J 1998, 19:55–62.
Smith FB, Lee AJ, Fowkes FRG, et al.: Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997, 17:3321–3325.
Smith FB, Rumley A, Lee AJ, et al.: Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998, 100:758–763.
Koch M, Kutkuhn B, Grabensee B, et al.: Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997, 12:2603–2611.
Sweetnam PM, Thomas HF, Yarnell JWG, et al.: Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. The Caerphilly and Speedwell Studies. Eur Heart J 1996, 17:1814–1820.
Koenig W, Sund M, Filipiak B, et al.: Plasma viscosity and the risk of coronary heart disease. Results from the MONICA-Augsburg Cohort Study 1984–1992. Arterioscler Thromb Vasc Biol 1998, 18:768–772.
Jose J, Selvakumar D, Selvakumar R, et al.: Plasma fibrinogen—an independent risk factor for ischaemic heart disease. Indian Heart J 1998, 50:45–48.
Markovitz JH, Kulkarni K, Goldschmidt-Clermont P, et al.: Increased platelet activation and fibrinogen in Asian Indians. Eur Heart J 1998, 19:720–726.
Folsom AR, Pankow JS, Williams RR, et al.: Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study. Thromb Haemost 1998, 2:400–404.
Rosenson RS: Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993, 22:933–940.
Lowe GDO: The impact of fibrinogen on arterial disease. Excerpta Medica 1993.
Eichner JE, Moore WE, McKee PA, et al.: Fibrinogen levels in women having coronary angiography. Am J Cardiol 1996, 78:15–18.
Tribouilloy Ch, Peltier M, Colas L, et al.: Fibrinogen is an independent marker for thoracic aortic artherosclerosis. Am J Cardiol 1998, 81:321–326.
Danielsen R, Önundarson PT, Thors H, et al.: Activated and total coagulation factor VII, and fibrinogen in coronary artery disease. Scand Cardiovasc J 1998, 32:87–95.
• Kruskal JB, Commerford PJ, Franks JJ et al.: Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987, 317:1361–1365.
First study to demonstrate an association between fibrinogen levels and unstable angina pectoris patients
• Becker RC, Cannon ChP, Bovill EG, et al.: Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial). Am J Cardiol 1996, 78:142–147.
Large prospective clinical study documenting the prognostic value of fibrinogen in patients with unstable angina pectoris and non-Q-wave infarction
Toss H, Lindahl B, Siegbahn A, et al.: Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997, 96:4204–4210.
• Verheggen PWHM, de Maat MPM, Manger Cats V, et al.: Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur Heart J 1999 [in press].
Interesting study showing that only inflammatory markers were predictive of clinical outcome, but not markers of coagulation activation and endothelial function in patients with unstable angina, refractory to medical treatment
Humphries SE: Genetic regulation of fibrinogen. Eur Heart J 1995, 16 (suppl A):15-20.
Carter AM, Mansfield MW, Stickland MH, et al.: ß-Fibrinogen gene — 455 G/A polymorphism and fibrinogen levels. Risk factors for coronary artery disease in subjects with NIDDM — Diabetes Care 1996, 19:1265–1268.
Humphries SE, Henry JA, Montgomery HE: Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Blood Coag Fibrinolysis 1999, (suppl 1):S17–S21.
Zito F, Di Castelnuovo A, Amore C, et al.: Bc1 I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients. Arterioscler Thromb Vasc Biol 1997, 17:3489–3494.
Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries S, et al.: A common mutation (G-455-A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest 1997, 99:3034–3039.
Montgomery HE, Clarkson P, Nwose OM, et al.: The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene. Arterioscler Thromb Vasc Biol 1996, 16:386–391.
Margaglione M, Cappucci G, Colaizzo D, et al.: Fibrinogen plasma level in an apparently healthy general populationrelation to environmental and genetic determinants. Thromb Haemost 1998, 80:805–810.
Folsom AR.: Fibrinogen and cardiovascular risk markers. Blood Coagul Fibrinol 1999, 10(suppl 1):S13-S16.
Scarabin P-Y, Aillaud M-F, Amouyel P, et al.: Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction. The Prime Study. Thromb Haemost 1998, 80:749–756.
Folsom AR, Peacock JM, Nieto FJ, et al.: Plasma fibrinogen and incident hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. J Hypertens 1998, 16:1579–1583.
Junker R, Heinrich J, Schulte H, et al.: Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Munster study. J Hypertens 1998, 16:917–923.
• Welty FK, Mittleman MA, Wilson PWF, et al.: Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham Offspring Population. Circulation 1997, 95:825–830.
Study suggesting that part of the effect of lipid-lowering is mediated by reducing thrombotic tendency
Danesh J, Peto R: Risk factors for coronary heart disease and infection with Helicobcter pylori: meta-analysis of 18 studies. Br Med J 1998, 316:1130–1132.
Regnstrom J, Jofinge S, Bavenholm P, et al.: Helicobacter pylori seropositivity is not associated with inflammatory parameters, lipid concentrations and degree of coronary artery disease. J Intern Med 1998, 243:109–113.
Koenig W, Rothenbacher D, Hoffmeister A, et al.: Infection with Helicobacter pylori is not a major independent risk factor for coronary heart disease: Lack of a role of CagA-positive strains and absence of a systemic inflammatory response. Circulation in press.
Toss H, Gnarpe J, Gnarpe H, et al.: Increased fibrinogen levels are associated with persistent Chlamydia penumoniae infection in unstable coronary artery disease. Eur Heart J 1998, 19:570–577.
Hoffmeister A, Rothenbacher D, Wanner P, et al.: Systemic inflammation, seropositivity to chlamydial lipopolysaccharide and coronary artery disease—a case-control study. Circulation in press.
Torgano G, Cosentini R, Mandelli C, et al.: Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma levels in patients with ischemic heart disease. Circulation 1999, 99:1555–1559.
Anderson JL, Muhlestein JB, Carlquist J, et al.: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. Circulation 1999, 99:1540–1547.
Hicks RCJ, Golledge J, Mir-Hasseine R, et al. Vasoactive effects of fibrinogen on saphenous vein. Nature 1996, 379:818–820.
Retzinger GS, DeAnglis AP, Patuto SJ.: Adsorption of fibrinogen to droplets of liquid hydrophobic phases. Functionality of the bound protein and biological implications. Arterioscler Thromb Vasc Biol 1998, 18:1948–1957.
Rabbani LE, Loscalzo J: Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atherosclerosis 1994, 105:1–7.
Schneider DJ, Taatjes DJ, Howards DB, et al.: Increased reactivity of platelets induced by fibrinogen independent of ist bindings to the IIb-IIIa surface glycoprotein;: A potential contributor to cardiovascular risk. J Am Coll Cardiol 1999, 33:261–266.
Fatah K, Hamsten A, Blombäck B, et al.: Fibrin gel network characteristics and coronary heart disease: Relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992, 68:130–135.
Scrutton MC, Ross-Murphy SB, Bennett GM, et al.: Changes in clot deformability — a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction. Blood Coagul Fibrinol 1994, 4:719–723.
• McDonagh J, Lee MH: How does hyperfibrinogenemia lead to thrombosis? Fibrinolysis & Proteolysis 1997, 11(suppl 1):13–17.
A paper alluding to the possibility that high fibrinogen levels might influence fibrinolysis by interfering with the plasminogen receptor
Koenig W, Ernst E: The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 1992, 94(2–3):93–107.
Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996, 96:874–877.
Danesh J, Collins R, Peto R: Chronic infections and coronary heart disease. Is there a link? Lancet 1997, 350:430–436.
Folsom AR, Wu KK, Rosamond WD, et al.: Prospective Study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997, 96:1102–1108.
Koenig W, Ernst E: Exercise and thrombosis. Coronary Artery Disease 1999 [in press].
Koenig W, Hoffmeister A, Hombach V: Hyperfibrinogenemia and cardiovascular risk: possible strategies for intervention. Fibrinolysis & Proteolysis 1997, (suppl 1): 41–46.
•• Kockx M, Gervois PP, Poulain P, et al.: Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-a. Blood. 1999 33:2291–2298
Excellent paper elucidating a potential mechanism responsible for the suppression of fibrinogen by fibrates
• Staels B, Koenig W, Habib A, et al.: Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARg activators. Nature 1998 393:790–793.
A paper dealing with possible antiatherogenic effects of fibrates
Palazon CP, Alfon J, Gaffney P, et al.: Effects of reducing LDL and increasing HDL with gemfibrozil in experimental coronary lesion development and thrombotic risk. Atherosclerosis 1998, 136:333–345.
Behar S for the BIP Study Group: Lowering fibrinogen levels: clinical update. Blood Coagul Fibrinol 1999, 10(suppl 1):S41-S43.
Prisco D, Paniccia R, Bandinelli B, et al.: Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease. Int J Clin Lab Res 1998, 28:170–173.
The Writing Group for the Estradiol Clotting Factors Study: Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A 1-year, double-blind, placebo-controlled study. Thromb Haemost 1996, 75:476–480.
Fröhlich M, Schunkert H, Hense HW, et al.: Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women. Br J Haematol 1998, 100:577–581.
Lip GYH, Blann AD, Jones AF, et al.: Effects of hormonereplacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: Implications for prevention of atherosclerosis. Am Heart J 1997, 134:764–771.
Walsh BW, Kuller LH, Wild RA, et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 1998, 279:1445–1451.
Giri S, Thompson PD, Taxel P, et al.: Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis 1998, 137:359–366.
O'Keefe JH, Kim SC, Hall RR, et al.: Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997, 29:1–5.
Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998, 280:605–613.
Rosenson RS, Tangney CC, Hafner JM: Intra-individual variability of fibrinogen levels and cardiovascular profile. Arterioscler Thromb 1994, 14:1928–1932.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koenig, W. Fibrinogen and coronary risk. Curr Cardiol Rep 1, 112–118 (1999). https://doi.org/10.1007/s11886-999-0068-y
Issue Date:
DOI: https://doi.org/10.1007/s11886-999-0068-y